Navigation Links
Abbott Completes Acquisition of Facet Biotech
Date:4/21/2010

ABBOTT PARK, Ill., April 21 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) has completed its acquisition of Facet Biotech Corporation, strengthening its pharmaceutical pipeline in immunology and oncology.

The acquisition provides Abbott with a promising biologic intended to treat multiple sclerosis (MS) and compounds that complement its existing diverse oncology program.  The new Abbott compounds include daclizumab – a Phase II investigational biologic intended to treat multiple sclerosis that is expected to move into Phase III development in the second quarter 2010 – and oncology compounds in early- to mid-stage development that are being studied to treat different types of cancer, including multiple myeloma and chronic lymphocytic leukemia.

"Facet's depth of biologics experience and sophisticated antibody engineering platforms complement Abbott's current R&D programs in oncology, immunology and other therapeutic areas," said John Leonard, M.D., senior vice president, global pharmaceutical research and development, Abbott.

The final step in the acquisition process was a short-form merger of Amber Acquisition Inc., a wholly-owned subsidiary of Abbott, with and into Facet Biotech Corporation. As a result of the merger, all outstanding shares of Facet common stock not tendered in the cash tender offer (other than those as to which holders properly exercise dissenters' rights) were converted into the right to receive $27 per share in cash, without interest and subject to any required withholding taxes.

About Abbott

Abbott is a global, broad-based health care company devot
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015  AVACEN, Inc. announced today the issue by the ... medical technology platform supporting its unique Dry Heat Therapy AVACEN ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... 9,066,781 - Methods And Apparatus For Therapeutic Application of Thermal ... methods of use, referred to by the company as the ...
(Date:7/1/2015)... 1, 2015 Radiant Insights announce ... Oxygen Concentrators Market Shares, Strategy, and Forecasts, Worldwide, ... continuing growth as the aging population worldwide needs homecare ... conditions where oxygen is able to improve the quality ... have become affordable and support a mobile lifestyle even ...
(Date:7/1/2015)... , July 1, 2015 ... is expected to reach USD 49,119.2 million by 2020, ... Inc. Monitoring services is expected to remain the dominant ... USD 1,227.5 million in 2012, and an estimated CAGR ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , Browse full ...
Breaking Medicine Technology:AVACEN Medical Patent Issued 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 3Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5
... following statement,by Andrea Kavanagh, Director of the Pure Salmon ... publish a study tomorrow that,shows sea lice from open ... wild fish stocks., "This study confirms what we ... havoc on wild salmon populations. If outbreaks of these,parasites ...
... Results, SOUTH SAN FRANCICSO, Calif., Dec. 13 ... announced that its oral syk,kinase inhibitor, R788 (tamatinib ... Arthritis (RA) patients in a,recently completed Phase 2 ... 150mg po bid (orally, twice daily), showed higher ...
Cached Medicine Technology:Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 2Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 3Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 4Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 5Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 6
(Date:7/1/2015)... Mesa, Arizona (PRWEB) , ... July 01, 2015 , ... ... recently opened a new office in the greater Phoenix area – their Mesa, ... the move to senior care with their purchase of the rights to the area ...
(Date:7/1/2015)... ... July 01, 2015 , ... Who doesn’t want a ... in life with a healthy balance between work and life, and positive friendships and ... new book, Positive Health: Flourishing Lives, Wellbeing in Doctors. , With a focus on ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... team as Director of Referral Relations. , Emily originally entered the behavioral ... she designed and implemented unique academic curriculum for clients to engage in their ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... and devices, today announced the opening of a new operational office in Zurich, ... that enables collaboration across all lines of business for organizations throughout the Swiss ...
(Date:7/1/2015)... ... , ... Recent research has revealed that most adults lack confidence in the ... professionals. Starting the last Monday of June, Whiter Image Dental will help ... on the customer’s first popular In-Office 2 Patient Kit. , The ...
Breaking Medicine News(10 mins):Health News:Amada Senior Care Expands to Greater Phoenix Area 2Health News:Medical Doctor Explains The Healthy Effects of a Positive Outlook in New Book 2Health News:Northbound Treatment Services Welcomes Emily Orrick as Director of Referral Relations 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 3Health News:Whiter Image Dental Offers New Customers Half-Off Teeth Whitening Kit 2
... treated in many cases, say US doctors. In peripheral artery ... blocked with the same kind of fatty deposits - plaque ... treating it is very simple - keep walking. While the ... ability to walk with ease. Positive effects are seen within ...
... Black Death during middle ages in Europe and now ... sequenced. The genes seem to be "unusually fluid", readily ... microbes. ,That could mean that more virulent strains of ... strains might be relatively easy to develop as weapons. ...
... ingredient in the -- depo medroxyprogesterone acetate or DMPA -- ... younger you are when you begin using this contraceptive, the ... // ,From the time we are born, ... down and re-building, usually in a well-balanced design that keeps ...
... pregnant women stopped smoking, say Australian researchers, arguing that healthcare ... quit.,They found that smoking doubles the risk of having a ... and triples the rate of SIDS - and if women ... cut their smoking by half to achieve any benefit for ...
... pressure on the nerves exiting the spine may lead ... the way your spine is aligned. The World Chiropractic ... on the nerves that exit the spine. And this ... ,The chiropractors call these misalignments and neurology problems ...
... the risk of a gastrointestinal bleed in older patients. ... of antidepressants which are very widely prescribed. They are ... of side effects. But, as Researchers at Ottawa Hospital ... ,Almost 314,000 patients aged 65 ...
Cached Medicine News:Health News:Sequencing of the Plague 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: